Rare sugar-based therapy for COVID-19 and other infectious diseases: D-Allose-based therapy for SARS-COV-2: D-Allose, the C-3 epimer of glucose, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides 13/August/2020, 2.55 pm

Natural product-based therapy for COVID-19 and other infectious diseases: Fucoidan-based therapy for SARS-COV-2: Fucoidan, a fucose-enriched and sulfated polysaccharide, inhibits SARS-COV-2/1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, Interferon-stimulated gene 15, and others 1/August/2020, 9.08 am
August 1, 2020
Salidorside-based regenerative cardiovascular therapy: Molecular mechanistic insight into how Salidorside protects against and promotes functional recovery after Myocardial Infarction: Salidorside inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration and survival after myocardial infarction, via up-regulation of its target gene, 16/August/2020, 4.03 pm
August 16, 2020
Show all

Introduction: What they say:

A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.” This study was published, in the 24 December 2009 issue of the journal “Cell” (the number 1 research journal in General Biology with an impact factor of 33),  by the 2015 Laskar award winner Prof. Stephen Elledge, Brass and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Rare sugar-based therapy for COVID-19 and other infectious diseases: D-Allose-based therapy for SARS-COV-2: D-Allose, the C-3 epimer of glucose, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides 13/August/2020, 2.54 pm


What is known?

Prof. Stephen Elledge research team has showed that interferon-inducible transmembrane proteins IFITM1, 2, and 3 inhibit  influenza A H1N1 virus, West Nile virus, and dengue virus replication, suggesting that increasing the expression of IFITM3 may confer resistance against these viruses. Other studies suggest that IFITM3 may also protect against Ebola virus, hepatitis C virus, yellow fever virus and SARS coronavirus etc.


From research findings to therapeutic opportunity: 

The rare sugar D-Allose (Monosaccharide) is found in the leaves of shrub protea rubropilosa, and others. It has been shown to  protect against salt-induced hypertension, brain/renal ischemia/reperfusion (I/R) injury and others. However, its mechanism of action remains largely elusive. 

I have published earlier that D-Allose could play a role in protecting against  infectious diseases caused by a number of viruses (https://genomediscovery.org/2018/03/sugar-based-anti-infective-therapy-d-allose-an-aldohexose-sugar-inhibits-hepatitis-b-c-dengue-zika-ebola-hiv-1-mtb-malaria-cmv-influenza-h1ni1-respiratory-syncytial/) and others (https://genomediscovery.org/page/2/?s=D-Allose).

This study suggests, for the first time, that D-Allose, with detailed mechanistic insights, could protect against COVID-19 [caused by SARS-COV-2 virus) and other infectious diseases (Fig.1). D-Allose, by increasing the expression of its target genes, it could increase the expression of IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides (Figs.1-4). Thereby, it could: (1) inhibit/prevent the entry/fusion/replication/production of  SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial,  Sindbis, and SFV viruses; (2) confer resistance against  infection caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV, Influenza H1NI1,  respiratory syncytical,  Sindbis, and SFV viruses; and (3) promote innate immunity (Figs. 1-6)

Furthermore, D-Allose could protect against clinical complications, such as acute respiratory distress syndrome, cytokine storm and others, caused by SARS-COV-2 in severe COVID-19 patients and others. 

Figure 1. Mechanistic insight into how D-Allose prevents/protects against SARS-COV-2. MMR vaccine inhibits SARS-COV-2 &  SARS-COV-1 through induction of its target genes, such as IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2, and others.

 

Figure 2 Mechanistic insight into how D-Allose functions as a broad spectrum anti-infective agent. D-Allose inhibits SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial , Sindbis, Foot and Mouth disease virus, ADV, and SFV viruses production through induction of its target genes, such as IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2, antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2 and others.

Figure 3.  D-Allose can be used to treat/prevent/boost one’s immunity against SARS-COV-2 and COVID-19.

Figure 4 Mechanistic insight into how D-Allose functions as a broad spectrum anti-infective agent. D-Allose inhibits SARS-COV-2 viruses production through induction of its target genes, such as IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2, antiviral Proteins IFITM3, Interferon-stimulated gene 15, Mx2 and others.

Figure 5.  D-Allose, derived from protea rubropilasa and others, can function as an immune booster against SARS-COV-2 and other infectious diseases, and thereby serves as a broad-spectrum anti-infective agent.

Figure 6.  Natural product-based (D-Allose) therapy for COVID-19 and other infectious diseases. GBMD (genomediscovery.org) is looking for Bio-Medical Scientists/Professor/Medical faculties/Clinicians who would be interested in collaborating with us in exploring the bio-medical mechanisms and in carrying out clinical trial.

Thus, pharmacological formulations encompassing “D-Allose or its derivatives or its mechanistic equivalents, either alone or in combination with other drugs/compounds, can be used to prevent/treat/protect against infections caused by SARS-COV-2, SARS-COV-1, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Foot and Mouth disease, ADV (Adenovirus), Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses (Figs. 1-5).


Details of the research findings: 

Idea formulated by Dr L Boominathan PhD

Undisclosed information: How D-Allose increases the expression of antiviral Protein IFITM3, Interferon-stimulated gene 15, & Mx2

Type: Research cooperation

For more details on research cooperation, you may reach us at drboomi@genomediscovery.org 


References: 

CitationBoominathan L, Rare sugar-based therapy for COVID-19 and other infectious diseases: D-Allose-based therapy for SARS-COV-2: D-Allose, the C-3 epimer of glucose, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpah/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides 13/August/2020, 2.55 pm

Courtesy: When you cite drop us a line at drboomi@genomediscovery.org,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Comments are closed.